HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Liberty Media invests in Borba

This article was originally published in The Rose Sheet

Executive Summary

QVC owner Liberty Media has acquired a stake in Borba LLC through its Liberty Interactive Group, the firm announces Aug. 15. The investment will enable Liberty to "participate in the value creation stemming from Borba's distribution through QVC." Terms of the deal were not disclosed. Borba, which sells beauty supplements and topical anti-aging products, debuted on QVC in May 2006. The company has sold almost $5 mil. worth of items on QVC since then, Liberty says. "BORBA is one of the most highly respected brands in this growing sector of the health and beauty business," QVC CEO Meade Rudasill says. Borba's items are also available at Sephora, Ulta, Macys and other national retailers...

You may also be interested in...

Borba Teams With Brewer To Market Drinkable Skin Care; QVC Owner Invests

Borba is looking forward to expanded distribution of its drinkable skin-care products and topical cosmeceuticals through a distribution agreement with Anheuser-Busch and the investment of Liberty Media Corporation, owner of QVC

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts